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Abstract
Introduction The purpose of this study was to identify brain
atrophy specific for dementia with Lewy bodies (DLB) and
to evaluate the discriminatory performance of this specific
atrophy between DLB and Alzheimer’s disease (AD).
Methods We retrospectively reviewed 60 DLB and 30
AD patients who had undergone 3D T1-weighted MRI.
We randomly divided the DLB patients into two equal
groups (A and B). First, we obtained a target volume of
interest (VOI) for DLB-specific atrophy using correla-
tion analysis of the percentage rate of significant whole
white matter (WM) atrophy calculated using the Voxel-
based Specific Regional Analysis System for Alz-
heimer’s Disease (VSRAD) based on statistical paramet-
ric mapping 8 (SPM8) plus diffeomorphic anatomic
registration through exponentiated Lie algebra, with seg-
mented WM images in group A. We then evaluated the
usefulness of this target VOI for discriminating the
remaining 30 DLB patients in group B from the 30
AD patients. Z score values in this target VOI obtained
from VSRAD were used as the determinant in receiver
operating characteristic (ROC) analysis.
Results Specific target VOIs for DLB were determined in
the right-side dominant dorsal midbrain, right-side dominant
dorsal pons, and bilateral cerebellum. ROC analysis
revealed that the target VOI limited to the midbrain
exhibited the highest area under the ROC curves of 0.75.
Conclusions DLB patients showed specific atrophy in
the midbrain, pons, and cerebellum. Midbrain atrophy
demonstrated the highest power for discriminating DLB
and AD. This approach may be useful for determining
the contributions of DLB and AD pathologies to the
dementia syndrome.
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Dementia with Lewy bodies (DLB) is the second most
common type of degenerative dementia, accounting for
up to 30 % of all cases of dementia [1]. In addition to
dementia, visual hallucinations, fluctuating cognitive im-
pairment, and parkinsonism are the main symptoms [2].
DLB is pathologically characterized by alpha-synuclein
inclusions in the brainstem, subcortical nuclei, limbic,
and neocortical areas [2]. Although the temporal se-
quence of symptoms and clinical features of DLB are
considered to be different from those of Parkinson’s
disease with dementia (PDD), discriminating PDD and
DLB is difficult in many cases. The accumulation of
abnormal neuronal alpha-synuclein inclusions is the de-
fining pathological process common to both PDD and
DLB [3]. In this study, PDD and DLB are dealt with as
a single pathogenic Lewy body disorder.
Nuclear medicine studies of the dopaminergic system
are best suited for detecting pathological states in DLB.
One of the more effective examinations for the differ-
ential diagnosis of DLB from Alzheimer’s disease (AD)
is 123I-MIBG myocardial scintigraphy. Yoshita et al.
found that the delayed heart-to-mediastinum uptake
(H/M) ratio had a sensitivity of 100 %, a specificity
of 100 %, and a positive predictive value of 100 % [4].
However, it should be noted that a decreased myocar-
dial MIBG uptake is not specific of DLB; in fact,
various heart diseases and diabetes may damage the
postganglionic sympathetic neurons, leading to false-
positive MIBG findings [5]. Hypometabolism or hypo-
perfusion in the occipital cortex are also useful for
distinguishing DLB from AD [6–8], although their ac-
curacies are not so high. Commonly, MRI has been
used to rule out other diseases manifesting dementia,
such as cerebral infarction, chronic subdural hematoma,
or normal pressure hydrocephalus, and this equipment is
more widely used without radionuclides or radiation
exposure, as is the case with positron emission tomog-
raphy (PET) or single photon emission computed to-
mography (SPECT).
Voxel-based morphometry (VBM), which objectively
assesses whole brain structure with voxel-by-voxel
comparisons, has been developed to analyze tissue con-
centrations or volumes between subject groups to dis-
tinguish degenerative diseases with dementia [9]. Some
studies comparing gray matter (GM) loss in DLB with
that of AD by means of VBM have shown similar
losses with relative preservation of the temporal lobes
in DLB [10–12]. One study with a relatively large
number of subjects found greater GM atrophy of the
dorsal midbrain in DLB than in AD [12], while others
have shown significant atrophy in specific subcortical
regions, such as the putamen [13] and basal forebrain
[14, 15].
Recently, the statistical parametric mapping 8 (SPM8)
plus diffeomorphic anatomical registration through expo-
nentiated Lie algebra (DARTEL; Wellcome Trust Centre
for Neuroimaging, London, UK) method was developed
for precise VBM [16] for both GM and white matter
(WM). DARTEL was shown to improve registration and
to provide precise, accurate localization of structural
damage and functional overlays. However, Takahashi
et al. showed no DLB-specific atrophy of WM com-
pared to AD using SPM8 plus DARTEL [17]. The
authors have insisted the GM attenuation in deep brain
GM, including the dorsal midbrain, detected in previous
studies may be attributed to incomplete registration to
the template.
There have been only a few studies evaluating WM
changes in DLB compared to AD and healthy controls
with VBM [17, 18]. One conventional VBM study
using SPM5 for analysis showed significant atrophy of
WM in the pons and medulla oblongata in idiopathic
Parkinson’s disease compared to healthy controls [18].
The other study using SPM8 plus DARTEL for analysis
showed no DLB-specific significant atrophy of WM
compared to AD [17].
The purpose of our study was to identify a DLB-
specific atrophy using SPM8 plus DARTEL and to
evaluate the performance of this specific focal atrophy
to discriminate between DLB and AD. Although the
previous SPM8 plus DARTEL study did not find any
DLB-specific atrophy [17], a recent study of antemor-
tem MRI and postmortem neuropathologic classification
of DLB and AD revealed that antemortem dorsal mes-
opontine atrophy was indicative of a high likelihood of
DLB [19], leading us to take notice of brain stem
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atrophy in DLB. Because SPM8 plus DARTEL classi-
fies most brain stem structures as white matter [16], we
focused on white matter changes in the present study.
Materials and methods
We retrospectively reviewed 60 patients with DLB (32
men and 28 women, 77.3±5.8 years of age) and 30
patients with AD (7 men and 23 women, 76.7±5.7 years
of age), who had undergone 3D T1-weighted structural
MRI from October 2009 to August 2011. All of the 60
patients with DLB had dementia and spontaneous fea-
tures of parkinsonism. Mini-mental state examination
(MMSE) scores were 20.8±4.1 (mean ± SD). Some of
them had fluctuating cognition with pronounced varia-
tions in attention and alertness, recurrent visual halluci-
nations that were typically well formed and detailed;
thus, they were diagnosed as possible/probable DLB
on the basis of the criteria proposed in the consortium
on DLB international workshop [2]. All of the 60
patients with DLB revealed reduced H/M ratios on
delayed phase of 123I-MIBG myocardial scintigraphy
which was used as an adjunct of differential diagnosis
of DLB and AD. The 30 patients with AD were diag-
nosed as probable AD according to the National Insti-
tute of Neurologic and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disor-
ders Association criteria [20, 21]. The MMSE scores of
the 30 AD patients were 20.4±4.1. All of AD patients
did not reveal reduced H/M ratios on either early or
delayed phases of 123I-MIBG myocardial scintigraphy.
The ethics committee of Toho University Sakura Medi-
cal Center approved this study and all subjects provided
informed consent to participate. None of them had
asymptomatic cerebral infarction detected by T2-
weighted MRI.
All 90 patients underwent MRI examinations on a
1.5T Gyroscan (Philips, Best, the Netherlands). One
hundred eighty 3D sections of a T1-weighted,
magnetization-prepared rapid acquisition of gradient-
echo (MPRAGE) sequence were obtained in a sagittal
orientation as 1-mm thick gapless sections (FOV
240 mm, TR 9.7 ms, TE 4.6 ms, flip angle 10°, and
TI 525 ms).
Using a free software program, the voxel-based spe-
cific regional analysis system for Alzheimer’s disease
(VSRAD) based on SPM8 plus DARTEL [22], we clas-
sified MRIs of all 90 patients into GM, WM, or
cerebrospinal fluid images using a unified tissue-
segmentation procedure after image-intensity nonunifor-
mity correction, anatomically standardized to a custom-
ized template of WM, and then smoothed using an 8-mm
full width at half maximum isotropic Gaussian kernel.
This new VSRAD software was upgraded from the pre-
vious SPM2 version [23]. VSRAD provides statistical Z
score images for WM atrophy in each of the patients
compared to that of the “normal” database of WM. The
Z score was defined as: ([control mean]− [individual
value]) / (control SD). The “normal” database bundled
with VSRAD comprised 80 healthy volunteers (37 men
and 43 women), aged 54 to 86 years who underwent 3D
T1-weighted MPRAGE sequence using a 1.5T Siemens
Vision Plus scanner (Siemens, Erlangen, Germany).
Their performance was within normal limits both on
the Wechsler Memory Scale—Revised and Wechsler
Adult Intelligence Scale—Revised [22]. Their MMSE
scores ranged from 26 to 30; 29.1±1.2.
We divided the 60 patients with DLB into two
groups at random (group A: 30 patients, group B: 30
patients). We obtained extent of significant WM atrophy
for the whole brain, that is, the percentage rate of the
coordinates with a Z value exceeding the threshold
value of 2 in the whole brain, in each patient as com-
pared with that of the “normal” database bundled with
VSRAD in group A. Then, to detect target volumes of
interest (VOI) for DLB correlation, we compared this
whole brain percentage rate of WM atrophy with that of
each voxel in the anatomically standardized and
smoothed WM images in group A using SPM8 and
their ages as a nuisance covariate. Global nuisance
effects were accounted for by including the global cova-
riate as a nuisance effect. The resulting set of values for
each contrast of negative or positive correlation consti-
tuted statistical parametric maps of the t statistic SPM
{t}. Main effects used whole-brain analyses with an
uncorrected threshold at voxel level of p<0.001 and a
cluster false discovery rate for the multiple comparison
correction.
We then evaluated the usefulness of this target VOI for
discriminating the remaining 30 DLB patients in group B
from the 30 AD patients. VSRAD provided statistical Z
score images for WM atrophy in each of the patients com-
pared to that of the “normal” database of WM. We obtained
Table 1 Regions in which WM negatively correlated with percentage
of whole WM atrophy in 30 DLB patients with DLB (group A)
Brain region Talairach coordinates t value
Side x y z
Cerebellum posterior lobe Rt 12 −52 −31 4.5
Cerebellum anterior lobe Lt −12 −42 −21 3.9
Midbrain Rt 4 −24 −11 3.4
Pons Rt 4 −39 −33 3.2
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the averaged positive Z score in the target VOI with MRI-
cron (http://www.mccauslandcenter.sc.edu/mricro/mricron/).
Using these averaged positive Z scores in the target VOI as a
threshold, we used JMP 7.0 (SAS Institute, Cary, North
Carolina) to determine receiver operating characteristic (ROC)
curves for discriminating DLB and AD patients. The program
Fig. 1 Statistical parametric
mapping (SPM) showing the
negative correlation of the per-
centage of whole WM atrophy
to that in various brain regions in
the 30 DLB patients in group A
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calculated the areas under the ROC curves (AUC; probability
of concordance), sensitivity, specificity, and accuracy.
Results
DLB patients in group A exhibited a significant negative
correlation of their percentage rate of significant whole WM
atrophy with that of voxels in the right-side dominant dorsal
midbrain, right-side dominant dorsal pons, and bilateral
cerebellum and no significant positive correlations (Table 1,
Fig. 1). The mean percentage rate of significant whole WM
atrophy was 5.3±7.7 % (0–35.6). From this negative corre-
lation, we determined a target VOI for DLB-specific atro-
phy. The target VOI was divided into three parts, and we
created five target VOIs, consisting of the dorsal midbrain,
dorsal pons, cerebellum, midbrain plus pons, and midbrain
plus pons plus cerebellum (Fig. 2). ROC analysis using the
averaged positive Z scores in these five target VOIs was
performed to discriminate the DLB patients in group B from
the AD patients (Fig. 3). A target VOI limited to the mid-
brain exhibited the highest AUC of 0.75, sensitivity of
80 %, specificity of 64 %, and accuracy of 72 %. A target
VOI limited to the midbrain plus pons exhibited an AUC of
0.74, sensitivity of 60 %, specificity 90 %, and accuracy of
75 %. A target VOI limited to the pons exhibited an AUC of
0.68, sensitivity of 47 %, specificity of 93 %, and accuracy
of 70 %. A target VOI limited to the cerebellum exhibited an
AUC of 0.50, sensitivity of 20 %, specificity of 90 %, and
accuracy of 55 %. A target VOI encompassing the midbrain
plus pons and cerebellum exhibited an AUC of 0.55, sensitiv-
ity of 23 %, specificity of 90 %, and accuracy of 56.5 %.
Fig. 2 Target volumes of
interest (VOIs) for DLB-
specific atrophy: a midbrain, b
pons, c midbrain plus pons, d
cerebellum, and e midbrain plus
pons plus cerebellum
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Discussion
The present study demonstrated DLB-specific WM atrophy
in the right-side dominant dorsal midbrain, right-side dom-
inant dorsal pons, and bilateral cerebellum. Right-side dom-
inancy may result from the feature of the present cohort of
DLB patients. The WM atrophy in these areas was more
frequently observed in DLB than in AD. Of these areas,
midbrain atrophy exhibited the most powerful discrimina-
tion of DLB and AD. These findings are consistent with
pathological findings showing that Lewy bodies move up
the brainstem into the midbrain and then to the forebrain
before spreading into the cortex [18, 24, 25].
Takahashi et al. found no significant DLB-specific WM
and GM atrophy compared to AD using SPM8 plus DARTEL
[17]. Both our current study and theirs accepted an uncorrect-
ed threshold of p<0.001, but only ours used more stringent
analysis of a cluster false discovery rate of p<0.05 for the
multiple comparison correction. This inconsistency might
arise from the differences in the cluster analyses or variability
in the clinical cohorts (e.g., dementia severity, symptom pre-
sentation) of DLB and AD, although age and MMSE scores
did not differ significantly in the two studies.
Distinguishing DLB from AD is important for choosing
appropriate treatments, because clinical symptoms are some-
times too similar to distinguish between the two. Our ROC
results showed that the use of VBM with SPM8 plus DAR-
TEL may not be as accurate as using 123I-MIBG myocardial
scintigraphy [4]. This may be partly due to the fact that a
majority of DLB patients have overlapping AD and DLB
Fig. 3 ROC curves for
discriminating DLB and AD
patients using averaged positive
Z scores in target VOIs as a
threshold: a midbrain, b pons, c
midbrain plus pons, d
cerebellum, and e midbrain plus
pons plus cerebellum
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pathologies. Thus, brain stem atrophy revealed by MRI may
play a complementary role in determining the contribution of
DLB and AD pathologies to the dementia syndrome.
Our study was possibly limited by several factors. Since
we did not have MRI data of normal control group, we
searched DLB-specific area for WM atrophy using a linear
correlation analysis of each patient’s WM image with sig-
nificant atrophy rate for the whole brain WM as compared
with “normal” database bundled with VSRAD. This indirect
comparison between different MRI scanners should be val-
idated in a further study based on the on-site normal data-
base. Whether the present target VOI obtained from DLB
versus normal is the best for DLB versus AD discrimination
should be also further evaluated in direct comparison of a
larger number of DLB and AD patients. However the pres-
ent target VOI locates in the midbrain where DLB showed
significant atrophy compared to AD in previous studies [12,
19]. We enrolled patients not only with probable DLB, but
also those with possible DLB, even though their 123I MIBG-
SPECT results showed reduced H/M ratios on delayed
phase images, and we did not assess the clinical severities
(i.e., Hoehn and Yahr Scores) of the DLB patients. In the
future, we intend to evaluate the usefulness of this target
VOI for differentiating other dementia diseases using VBM
with SPM8 plus DARTEL as well as the usefulness of
combining this VBM analysis with other imaging modali-
ties, including SPECT and PET and their relationship to the
findings of postmortem neuropathology.
Conclusions
Our VBM analysis using SPM8 plus DARTEL demonstrated
significant WM atrophy in the dorsal midbrain, dorsal pons,
and cerebellum in the patients with DLB. Of these areas with
DLB-specific WM atrophy, the midbrain atrophy exhibited
the highest power for discriminating DLB from AD. This
VBM approach may be useful for determining the contribu-
tions of DLB and AD pathologies to the dementia syndrome.
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